Author: DFNS


BARDA and Sanofi Prepare for Studies of COVID-19 Vaccine

BARDA and Sanofi Pasteur, the vaccines global business unit of Sanofi, are expanding their collaboration to develop a SARS-CoV-2 vaccine. The previously announced research for a COVID-19 vaccine using a recombinant DNA platform will...


Pandora Report: 4.17.2020

A Strategic Vision for Biological Threat Reduction: The U.S. Department of Defense and Beyond The Committee on Enhancing Global Health Security through International Biosecurity and Health Engagement Programs of the National Academies of Sciences,...


Covid-19: National security events – 17 April 2020

Americas Argentina – Logistics – 16 April 2020: Argentine navy personnel from the Marine Infantry Battalion No 3 distributed food packets to civilians in Zárate. Brazil – Medical assistance – 16 April 2020: A...


FDA Accepts for Priority Review BLA for REGN-EB3 to Treat Ebola

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a new Biologics License Application (BLA) for REGN-EB3, an investigational triple antibody cocktail treatment for Ebola virus...


Europeans on UN Security Council condemn North Korean tests

United Nations, United States (AFP) March 31, 2020 – The European members of the UN Security Council on Tuesday condemned North Korea’s latest missile tests, describing the launches as “provocative actions.” Belgium, Estonia, France,...


BARDA Facilitates Development of Immunotherapies for COVID-19 Patients

The U.S. Department of Health and Human Services (HHS) will collaborate with multiple non-government organizations on the development of convalescent plasma and hyperimmune globulin immunotherapies. These treatments would use antibodies against SARS-CoV-2 from COVID-19...

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.